A revolutionary new test being piloted by the NHS can diagnose the specific type of brain tumour in as little as two hours, drastically reducing the previous waiting time of up to eight weeks. This rapid diagnosis allows patients to begin crucial treatments such as radiotherapy and chemotherapy much sooner, while also alleviating the prolonged anxiety associated with waiting for results.

This groundbreaking genomic test analyzes the genetic code of a tumour sample, providing doctors with vital information about its type. With approximately 150 different kinds of brain tumours, each requiring a tailored treatment approach, this speedier diagnosis is critical. Previously, determining the precise tumour type involved lengthy molecular and genetic analysis, often taking several weeks.

Steve Palmer, a 55-year-old from Nottingham, has already benefited from this new technology. His diagnosis was confirmed while he was still undergoing surgery to remove his glioblastoma, a grade 4 brain tumour. Palmer described the swift diagnosis as removing "weeks of anxiety," enabling him to focus on the next stages of his treatment and recovery.

Consultant neurosurgeon Stuart Smith, who led Palmer's operation, called the test "almost magical." He explained that knowing the tumour type during surgery can significantly influence the surgical approach. For curable tumours, a more aggressive removal is possible, whereas for aggressive types, surgeons can be more cautious to minimize potential brain damage.

The test involves sending small tissue samples from the tumour to a pathology lab. These samples are then processed for analysis by a portable sequencing machine from Oxford Nanopore. Specialist software, developed at the University of Nottingham in collaboration with hospital clinicians, interprets the data. The machine identifies the tumour's unique genomic fingerprint by analyzing DNA molecules as they pass through a nanopore, a microscopic hole.

In Palmer's case, the nanopore machine provided results within 20 minutes, allowing the neuropathology team to inform the surgical team that the tumour was likely a glioblastoma. Dr. Simon Paine, a consultant neuropathologist involved, stated that this genomic testing offers unparalleled clarity compared to traditional microscopic examination of tumour cells.

This advancement could also expedite patient access to clinical trials, as detailed information about the tumour's genetic makeup becomes available almost immediately. The pilot program is being rolled out in specialist centres across England, marking a significant step forward in neuro-oncology care.

The potential for quicker, more accurate diagnoses holds immense promise for improving patient outcomes in brain tumour treatment, offering hope and a faster path to care for those affected by these challenging conditions.